Portfolio Lab

Madrigal Pharmaceuticals, Inc.

  • Stock
  • Ticker MDGL
  • ISIN US5588681057
  • Nasdaq

Health care · Pharmaceuticals · USA

$379.10 −4.45%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Madrigal Pharmaceuticals, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

MDGLGlobal equities (VT)

$10,000 grew to $229,758. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −82.2% in 01/2022, measured from the peak in 06/2018. It took 77 months to get back to the old peak.

1-year return
−30.1%
5-year return p.a.
+35.7%
10-year return p.a.
+36.8%
Volatility p.a.
134.1%
Largest decline
−82.2%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue103137213287321311364431
Gross profit–133––––––
Operating income-67-79-47-114-60-93-5656
EBITDA-67-79-47-114-59-92-5656
Net income-59-73-42-114-59-94-5855
Earnings per share2.00-2.61-1.50-4.01-2.03-3.25-1.991.83
Balance sheet
Total assets1,0429971,0151,3621,2601,2271,2451,434
Liabilities288286319737657684721807
Equity754711696626603543524627
Cash100184186296199227293515
Long-term debt118118118340340340341341
Cash flow
Operating cash flow-104-89-4780-133-16723121
Capital expenditure-0.20.00.0-0.90.4-3.8-4.3-3.9
Free cash flow-105-89-4779-133-17119117

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +516.0%, weakest 2021 at −23.8%. 6 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
3 Nov 2026$1.83
30 Jul 2026−$1.99
6 May 2026−$3.25
19 Feb 2026−$2.03
4 Nov 2025−$4.01
5 Aug 2025−$1.50
1 May 2025−$2.61
26 Feb 2025$2.00
31 Oct 2024−$4.92
7 Aug 2024−$7.10
7 May 2024−$7.38
28 Feb 2024−$5.68

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€8.0bn
Market cap in trading currency
$8.81bn
Enterprise value
$8.19bn
P/E
–
P/S
6.17
P/B
14.05
EV/Sales
5.73
EV/EBITDA
–
Earnings yield
–
FCF yield
-1.9%

Results (last four quarters)

Revenue
$1.43bn
Gross profit
–
EBITDA
−$151m
Net income
−$155m
Earnings per share
−$5.44
Revenue per share
$61.47
Revenue growth
+50.1%
Earnings growth
–

Profitability

Gross margin
–
Operating margin
-10.7%
Net margin
-10.9%
Return on equity
-24.8%
Return on assets
-10.8%

Balance sheet and cash flow

Cash
$961m
Cash per share
$41.37
Financial debt
$341m
Debt/equity %
54
Current ratio
3.05
Book value per share
$26.99
Operating cash flow
−$157m
Free cash flow
−$169m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
23.2m
Volume
327,823
Avg. volume 3 months
356,696
Relative volume
0.9

Price and technicals

Price
$379.10
1 day
−4.4%
52-week high
$602.83
52-week low
$379.10
Distance to 52-week high
−37.1%
Distance to 52-week low
0.0%
Distance to 50-day line
−18.0%
Distance to 200-day line
−23.3%
RSI (14)
26
Volatility 1M
50.7%

Performance

1 week
−11.3%
1 month
−16.4%
3 months
−26.0%
6 months
−26.7%
YTD
−34.9%
1 year
−31.8%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has MDGL performed since 11/2016?

$10,000 grew to $229,758 by 20 Nov 2026, which is +36.8% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is MDGL?

Volatility was 134.1% per year, measured on monthly returns. The largest decline from a peak was −82.2%, with the low in 01/2022.

How does MDGL compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, MDGL returned +36.8% at 134.1%. The correlation of monthly returns was 0.03; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Madrigal Pharmaceuticals, Inc. (MDGL): Return and risk